UDK: 617.7-007.681:617.7-089

EXPERIENCE OF LUCENTIS APPLICATION IN TREATMENT OF NEOVASCULAR GLAUCOMA AGAINST THE BACKGROUND OF PROLIFERATIVE DIABETIC RETINOPATHY

A.S. Zotov1, A.S. Balalin1, S.V. Balalin1,2, Yu.Yu. Khzardzhan1, T.G. Yefremova1

1ФГАУ «НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Фёдорова» Минздрава России, Волгоградский филиал, Волгоград; 2ФГБОУ ВО «Волгоградский государственный медицинский университет» Министерства здравоохранения Российской Федерации кафедра офтальмологии

Abstract

The study involved 23 patients (23 eyes) with neovascular glaucoma against the background of proliferative diabetic retinopathy. The first stage was the intravitreal injection of Lucentis, then with IOP > 25 mm Hg – transscleral cyclophotocoagulation and after 2 weeks panretinal laser coagulation in ischemic zones; with IOP  25 mm Hg – panretinal laser coagulation in ischemic zones. At all observation periods there was a statistically significant decrease in IOP and in rubeosis. One week after the last stage of treatment the overall decrease in IOP was 33.4 % of the initial values, rubeosis was not detected. The application of Lucentis in combination with transscleral cyclophotocoagulation in the treatment of neovascular glaucoma against the background of proliferative diabetic retinopathy allows to achieve stable IOP normalization, preserving residual visual functions and reducing the risk of hemorrhagic complications.

Keywords

diabetic retinopathy, neovascular glaucoma, cyclophotocoagulation.

Contacts

Балалин Сергей Викторович – д. м. н., профессор кафедры офтальмологии института НМФО ФГБОУ ВО ВолгГМУ Минздрава России, заведующий научным отделом Волгоградского филиала ФГАУ «НМИЦ «МНТК «Микрохирургия глаза» им. акад. С.Н. Фёдорова» Минздрава России, e